The stock of Sangamo Biosciences, Inc. (NASDAQ:SGMO) hit a new 52-week low and has $3.05 target or 14.00% below today’s $3.55 share price. The 6 months bearish chart indicates high risk for the $250.70 million company. The 1-year low was reported on Oct, 28 by Barchart.com. If the $3.05 price target is reached, the company will be worth $35.10M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 464,726 shares traded hands. Sangamo Biosciences, Inc. (NASDAQ:SGMO) has declined 30.04% since March 28, 2016 and is downtrending. It has underperformed by 34.75% the S&P500.
Sangamo Biosciences, Inc. (NASDAQ:SGMO) Ratings Coverage
Out of 9 analysts covering Sangamo Biosciences (NASDAQ:SGMO), 5 rate it a “Buy”, 1 “Sell”, while 3 “Hold”. This means 56% are positive. Sangamo Biosciences has been the topic of 11 analyst reports since August 8, 2015 according to StockzIntelligence Inc. As per Thursday, September 3, the company rating was maintained by JP Morgan. As per Wednesday, October 19, the company rating was downgraded by PiperJaffray. The firm has “Neutral” rating given on Thursday, August 4 by Janney Capital. The stock of Sangamo Biosciences, Inc. (NASDAQ:SGMO) earned “Buy” rating by Jefferies on Wednesday, September 2. The stock has “Sell” rating given by Zacks on Tuesday, September 8. Piper Jaffray downgraded the shares of SGMO in a report on Wednesday, October 19 to “Neutral” rating. The firm has “Outperform” rating given on Friday, December 4 by Wells Fargo. The firm has “Buy” rating given on Friday, September 4 by Cowen & Co. The stock of Sangamo Biosciences, Inc. (NASDAQ:SGMO) earned “Buy” rating by Wedbush on Wednesday, September 2. On Friday, October 23 the stock rating was reinitiated by Jefferies with “Buy”.
According to Zacks Investment Research, “Sangamo BioSciences, Inc. is a leader in the development of novel transcription factors for the regulation of gene expression. Transcription factors are proteins that turn genes on or off by recognizing specific DNA sequences. The Universal Gene Recognition technology platform enables the engineering of a class of transcription factors known as zinc finger DNA binding proteins.”
Insitutional Activity: The institutional sentiment decreased to 0.81 in 2016 Q2. Its down 0.57, from 1.38 in 2016Q1. The ratio turned negative, as 20 funds sold all Sangamo Biosciences, Inc. shares owned while 42 reduced positions. 13 funds bought stakes while 37 increased positions. They now own 45.72 million shares or 4.72% less from 47.99 million shares in 2016Q1.
Washington Tru Savings Bank accumulated 0% or 3,000 shares. Beacon reported 4,950 shares or 0% of all its holdings. Dimensional Fund Advsrs Limited Partnership reported 111,174 shares or 0% of all its holdings. Vanguard Grp Incorporated has invested 0% of its portfolio in Sangamo Biosciences, Inc. (NASDAQ:SGMO). Raymond James Fincl Services last reported 12,783 shares in the company. Connor Clark Lunn Inv Mngmt holds 163,709 shares or 0.01% of its portfolio. First Republic Inv Management, a California-based fund reported 19,500 shares. Tiaa Cref Invest Management Limited Com last reported 0% of its portfolio in the stock. Fifth Third Bank & Trust holds 0% of its portfolio in Sangamo Biosciences, Inc. (NASDAQ:SGMO) for 400 shares. The Pennsylvania-based Nationwide Fund has invested 0% in Sangamo Biosciences, Inc. (NASDAQ:SGMO). Capital Fincl Advisers Limited Liability Corporation has 0% invested in the company for 32,214 shares. Princeton Cap Management owns 124,395 shares or 0.5% of their US portfolio. First Eagle Investment Mgmt Ltd last reported 0% of its portfolio in the stock. Qs Ltd Liability Co last reported 0.01% of its portfolio in the stock. Blackrock Invest Mngmt Ltd Limited Liability Company last reported 0% of its portfolio in the stock.
More news for Sangamo Biosciences, Inc. (NASDAQ:SGMO) were recently published by: Fool.com, which released: “Why Sangamo Biosciences, Inc. Fell 29% Today” on August 04, 2016. Prnewswire.com‘s article titled: “Sangamo BioSciences Announces Participation In Upcoming Scientific Conferences” and published on October 17, 2016 is yet another important article.
SGMO Company Profile
Sangamo Biosciences Inc., incorporated on June 22, 1995, is a clinical-stage biopharmaceutical company. The Firm is focused on the research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. The Firm is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics, which are therapeutic products for the treatment of genetic disease. The Company’s ZFP Therapeutic, SB-728, a ZFP nuclease (ZFN)-modified autologous cell product for the treatment of Human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS), is the therapeutic application of its ZFN genome editing technology and is being evaluated in an ongoing Phase II study of ZFN-modified T-cells (SB-728-T-1101, Cohort 3) and a Phase I/II study of modified hematopoietic stem cells (SB-728mR-HSPC) in HIV-infected subjects. The Firm has preclinical programs in hemophilia A and other Lysergic acid diethylamide (LSDs), and research stage programs in other monogenic diseases, including certain central nervous system (CNS) disorders and cancer immunotherapy.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.